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Chemokines are best known for their classic leukocyte chemotactic activity, which is crit-
ical for directing the immune response to sites of infection and injury. However, recent
studies have suggested that at least some chemokines may also interfere with infec-
tious agents directly. Antimicrobial chemokines tend to contain amphipathic alpha helical
secondary structure, and broad-spectrum activity against both Gram-positive and Gram
negative bacteria, as well as fungi. Conversely, several bacteria have been identified that
possess mechanisms for specifically blocking the antimicrobial activities of chemokines.
Although the precise mechanisms by which chemokines and microbes disarm one another
in vitro remain unknown, there is now emerging evidence in vivo that such interactions may
be biologically significant. More research will be needed to determine whether chemokines
with direct antimicrobial activity may be translated into a novel class of antibiotics.
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INTRODUCTION
Chemokines comprise a family of phylogenetically related, small
proteins whose main shared function is to recruit leukocytes to
sites of inflammation and infection (Murphy, 2008). In addi-
tion, some chemokines are important for tissue repair, organ
development, and cancer. Many chemokines have been shown to
have direct antimicrobial properties in vitro, however the in vivo
significance of this has not been established.
Chemokines are classified according to the number and
arrangement of conserved cysteine residues (Murphy et al., 2000).
In humans, all but two chemokines contain four conserved cys-
teine residues with disulfide bonds linking C1–C3 and C2–C4
(Figure 1). The first two cysteines are adjacent (CC motif, n= 24),
separated by one amino acid (CXC motif, n= 17), or separated
by three amino acids (CX3C motif, n= 1). The XC chemokines
(n= 2) have only two cysteines. Sequence identity is <30%
between members of different classes, but within the same class,
sequence identity ranges from ∼30 to 99% within species. Most
chemokines are cationic and∼7–12 kDa in molecular weight.
Although some chemokines are constitutively expressed, the
majority are induced under inflammatory conditions, often in
response to pleiotropic cytokines. Inducible chemokines are
involved in host defense (both innate and adaptive immunity),
and in acute and chronic inflammation. There are chemokines spe-
cialized for recruitment of neutrophils (CXCL1, CXCL2, CXCL8),
monocytes (CCL2, CCL7, CCL13), Th1cells (CXCL9, CXCL10,
CXCL11), Th2 cells (CCL17 and CCL22), Th17 cells (CCL20), and
other immune cells to sites of trauma, ischemia, and infection
(Olson and Ley, 2002; Singh et al., 2008). During the course of an
infection, pathogens may be exposed to many chemokines.
HISTORY OF ANTIMICROBIAL CHEMOKINES
Antimicrobial activity was discovered for chemokines in the year
2000 with the identification of truncated forms of CXCL7 as
platelet microbicidal proteins (Krijgsveld et al., 2000). Blood
platelets have been known to release antibacterial proteins upon
thrombin activation in vitro (Yeaman, 1997). These antimicro-
bial proteins, designated as thrombocidins, had both antibac-
terial and antifungal properties and were identified as C-
terminal deletion products of CXCL7 by protein sequencing.
Within the next several years, other investigators discovered addi-
tional chemokines (CXCL9, CXCL10, CXCL11, CXCL6, CXCL14,
CCL20, and CCL28) that had antimicrobial properties (Cole et al.,
2001; Hieshima et al., 2003; Yang et al., 2003; Linge et al., 2008;
Maerki et al., 2009). Since these chemokines can be induced during
inflammatory conditions, they may act as the first line of defense
against pathogens.
ANTIMICROBIAL ASSAY
Antimicrobial effects of chemokines were discovered in vitro with
a gel overlay assay and quantified by microdilution comparison,
or radial diffusion methods (Krijgsveld et al., 2000; Cole et al.,
2001; Yang et al., 2003). In the gel overlay assay, a lysate with
known antimicrobial properties is separated by SDS-PAGE. Next,
the pathogen to be tested is resuspended in nutrient poor agar
and poured onto a tissue culture plate (Figure 2). Then, a portion
of the SDS-PAGE gel is cut and placed on top for several hours
to allow transfer of proteins from gel to agar. The gel is removed
and a nutrient rich agar is placed on top. After overnight incuba-
tion, band areas without pathogen growth represent the location
of antimicrobial proteins.
For quantitative analysis, microdilution comparison and radial
diffusion methods have been used. For microdilution comparison,
a known amount of a pathogen is incubated with increasing con-
centration of antimicrobial chemokine in a nutrient poor broth.
After several hours, the number of viable organisms is determined
by serial dilution on nutrient rich agar plates. Percent inhibi-
tion is determined by the difference of viable organisms between
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FIGURE 1 | Cysteine disulfide bonds in different classes of chemokines.
In CC chemokines, the first two conserved cysteines are adjacent. The first
and the third, and the second and the forth conserved cysteines form
disulfide binds. In CXC chemokines, the first two conserved cysteines are
separated by one amino acid. In the CX3C chemokine, three amino acids
separate the first two conserved cysteines. There are only two conserved
cysteines in the XC class of chemokines. The name and number of human
members in each class of chemokines are on the right.
chemokine treated and untreated samples using the formula: [(
w/o chemokine)− ( w/chemokine)/( w/o chemokine)]× 100.
In the radial diffusion assay, organisms are mixed into nutrient
poor agar. Then, 3 mm diameter wells are punched out of the agar.
Next, a known concentration of chemokine is added to the wells
and incubated for several hours to allow protein diffusion. Finally,
a media rich agar is overlay on top. After overnight incubation, the
diameters of clear zone surrounding the wells are measured and
used to calculate the potency of the chemokine against the test
organism.
SALT DEPENDENCE OF CHEMOKINE ANTIMICROBIAL
ACTIVITIES
The nutrient poor agar and broth, described above, all contained
low ionic concentrations, with most assays having 10 mM of Na+.
As the Na+ concentration is increased to 100 mM, the antimi-
crobial activity of chemokines diminishes or even disappears.
Table 1 lists the reported electrolyte concentration of different
fluid compartments in humans. In particular, sweat and mucosal
secretions, such as saliva, have low ionic conditions that would
favor antimicrobial activities. Therefore knowing whether antimi-
crobial chemokines are secreted into these fluids is important.
Indeed, several chemokines have been reported in sweat (CXCL8
and CCL2) and in saliva (CXCL8; Jones et al., 1995; Yang et al.,
2005). Theoretically, chemokines may inhibit growth of organ-
isms on the skin and mucosal surfaces, provided they are in high
enough concentrations for antimicrobial activity.
CONCENTRATION OF CHEMOKINES NEEDED FOR
ANTIMICROBIAL ACTIVITY
For most antimicrobial chemokines, micromolar concentrations
are needed for pathogen killing (Krijgsveld et al., 2000; Cole et al.,
2001; Yang et al., 2003; Maerki et al., 2009; Yung et al., 2011). In
contrast, leukocyte chemotaxis in vitro typically requires 1000-fold
lower concentrations of chemokine (Berkhout et al., 1997; Siveke
and Hamann, 1998). A non-comprehensive list of chemokine con-
centrations found constitutively in different body fluids is listed in
Table 2. The most extensive survey has been obtained by bronchi-
olar alveolar lavage (Pacheco-Rodriguez et al., 2009). In general,
FIGURE 2 | Antimicrobial gel overlay assay. Proteins within a lysate with
known antimicrobial properties are separated by SDS-PAGE. A nutrient poor
agar with low sodium concentration is mixed with pathogen to make up the
bottom layer. A piece of the SDS-PAGE gel stab is placed on top for several
hours for proteins to diffuse from the gel onto the agar. The gel is then
removed and a nutrient rich agar placed on top. After overnight incubation, a
clear zone with no pathogen growth represents locations of antimicrobial
proteins.
naturally occurring chemokine concentrations are in the picomo-
lar to nanomolar range. However, two chemokines produced by
platelets are found at micromolar concentrations in serum (Brandt
et al., 2000). CXCL4 (also known as platelet factor 4) was the
first chemokine ever to be characterized. It binds to the recep-
tor CXCR3B, a splice variant affecting the N-terminus. The other
is CXCL7 (also known as neutrophil-activating peptide 2). Both
chemokines are released during platelet activation. From the table,
it is apparent that many chemokines are made constitutively and
secreted into serum/plasma, sweat, tears, saliva, and breast milk.
During infection and inflammation, chemokine concentra-
tions in biological fluids may be greatly increased (Luster, 1998).
For example, inflamed tonsils have nanomolar concentrations
of CXCL9, CXCL10, and CXCL11 whereas in normal unin-
flamed tonsils these chemokines are not detectable (Egesten et al.,
2007). Nanomolar concentrations of CXCL9 are sufficient to
inhibit Streptococcus pyogenes growth in vitro. However, in most
infection models, the concentrations of chemokines detected
in biological fluids are not sufficient for antimicrobial activi-
ties in vitro. Therefore, the combined effect of all antimicro-
bial chemokines present in the infection site may be needed
to achieve antimicrobial effects. However, we are not aware of
any data showing that antimicrobial chemokines have additive
or synergistic effects. In our own unpublished studies, we had
problems obtaining consistent inhibition data at low chemokine
concentrations to perform combination chemokine experiments.
Another possibility is that the concentration of chemokines on
mucosal surfaces may be much higher than in secretions because
many chemokines can bind glycosaminoglycans on cellular sur-
faces.
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Table 1 | Electrolytes concentration and major components in different human secretions.
Fluid Sodium
(mmol/L)
Chloride
(mmol/L)
Potassium
(mmol/L)
Bicarbonate
(mmol/L)
Phosphate
(mmol/L)
Creatinine
(mmol/L)
Others
(mmol/L)
Serum1 136–145 98–106 3.5–5.0 23–28 0.97–1.45 7–13
Sweat2 15–90 <40 0.002 2–40
Saliva3 2–50 5–40 10–36 25 1.4–39
Tears4 120–177 87–137 13–24
Nasal5 100–140 100–160 10–25
Urine6 10–200 15–200 10–0 <0.1–low 133–221 mmol/kg
per 24 h
Bile7 200–260 10–60 5–8 10–60 Taurocholate
100–260
Gastric juice8 100 280 15
Pancreatic juice8 150 40 5
Intestinal fluid8 150 100 5
Stool8 44–112 29–147
Diarrh8 3–139 15–115
Milk9 5–8 9–13 11–15 Lactose
193–207
PBS 137 139.7 2.7 10
Listed are the major ions found in human secretions. Major compounds such as creatinine, taurocholate, and lactose in urine, bile, and milk are also indicated.
1MAKSAP 14 Normal Laboratory Values. American College of Physicians, Copyright 2005. All rights reserved
2Bulmer and Forwell (1956), Kaiser et al. (1974).
3Chicharro et al. (1994).
4Lew et al. (2005).
5Cavaliere et al. (1988), Cavaliere et al. (1989).
6Moritz (2008).
7Wheeler et al. (1960).
8Shiau (1987).
9Koo and Gupta (1982), Wack et al. (1997).
RANGE OF ORGANISMS AFFECTED BY ANTIMICROBIAL
CHEMOKINES
Antimicrobial chemokines have been shown to inhibit a broad-
spectrum of organisms: Gram-positive bacteria, Gram negative
bacteria, and dimorphic fungi. Table 3 summarizes currently
available information on this subject. In general, most antimi-
crobial chemokines have activity against multiple organisms. This
suggests that the mechanism for antimicrobial activity is either
through a conserved or non-specific pathway. All highly active
antimicrobial chemokines have basic or cationic charge, but not
all cationic chemokines have antimicrobial properties.
Chemokines have been surveyed most comprehensively for
antimicrobial activity in the case of Staphylococcus aureus and
Escherichia coli. Of 45 chemokines tested, 22 were found to
have some anti-staphylococcal activity (Yung et al., 2011). For
E. coli, 25 of 33 chemokines tested had some activity (Yang
et al., 2003). A report on S. pyogenes showed that CXCL9,
CXCL10, and CXCL11 can exert antimicrobial activities even at
150 mM sodium concentration (Egesten et al., 2007). Likewise, the
antimicrobial effect of CXCL9, CXCL10, and CXCL11 on Bacil-
lus anthracis may also be independent of ionic concentrations
(Crawford et al., 2010). These chemokines were able to inhibit
both spore germination and bacillus viability in culture media.
In addition to bacteria, several chemokines also have antifun-
gal properties against Cryptococcus neoformans and Candida
albicans.
COMPARISONWITH OTHER ANTIMICROBIAL PROTEINS
Antimicrobial chemokines represent a fraction of known antimi-
crobial proteins.
In general, antimicrobial proteins can be divided into three
different classes. The largest class consists of β-stranded proteins
with four to six conserved cysteines linked by disulfide bonds.
Defensins and chemokines are members of this class. Whereas
chemokines typically have four conserved cysteines that form two
disulfide bonds, defensins have six conserved cysteines that form
three disulfide bonds to stabilize β-strands. Both β-defensins and
chemokines have overall cationic charge.
The antimicrobial effect of defensins occurs at micromolar
concentration and in low sodium conditions just as antimi-
crobial chemokines. For example, micromolar concentrations
of human beta defensin two are required for activity against
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Table 2 | Chemokine concentrations in different body fluids.
Chemokine Size MW
(kD)
Serum or plasma
nM
BAL
(nM)
Sweat
(nM)
Tears
(nM)
Saliva
(nM)
Parotid Secr
(nM)
Breast milk
(nM)
Family Member
CXC ELR+ CXCL1 7.8 0.01D 3.07T 0.4I
CXCL2 7.9 0.03X 5.96I
CXCL3 7.9 0.09P 0.62I
CXC ELR− CXCL4 7.8 1100B
CXC ELR+ CXCL5 8.0 0.12D 0.56T 0.66I
CXCL6 7.9 0.04R 0.001I
CXCL7 7.6 3200B 0.02I
CXCL8 8.4 0.003L 0.22T 0.02A 0.038V 0.03O 0.01I
CXC ELR− CXCL9 11.7 0.012M 0.32T 0.01K
CXCL10 8.5 0.009K 0.22T 0.358V 0.008Y 0.06K
CXCL11 8.3 0.005S 0.08T
CXCL12 8.0 0.3S 1.74T 0.005Y
CXCL13 10.3 0.003U 0.000Y
CXCL14 9.4 0.11W
CXCL16 10.1 0.26Q 0.02T
CXCL17 11.5 <0.005z
CX3C CX3CL1 8.5 0.1P 0.005V
C XCL1 10.0 0.08P 0.23T
CC CCL1 8.5 0.003P 0.04T
CCL2 8.6 0.02E 0.55T 0.01A 0.019V 0.044Y
CCL3 7.8 0.003E 0.19T 0.004Y
CCL4 7.6 0.001P 0.17T 0.001V
CCL5 7.8 1.79E 0.05T 0.009V 0.000Y 0.003F
CCL7 9.0 0.003P 0.03T
CCL8 8.9 0.002P 0.05T
CCL11 8.3 0.01P 0.13T 0.007V 0.006F
CCL13 8.6 0.026P 0.03T
CCL14 8.4 1.31C
CCL15 10.1 0.1P
CCL16 11.2 0.42P
CCL17 8.0 0.02S 0.04T
CCL18 7.8 4.23J
CCL19 8.8 0.009P 0.02T
CCL20 8.0 0.001S 0.11T
CCL21 12.2 0.01S 0.12T
CCL22 8.1 0.07S 0.07T
CCL23 11.3 0.036P
CCL24 8.8 0.025H
CCL25 14.2
CCL26 8.4 0.004H
CCL27 10.2 0.038S
CCL28 12.3 0.004N 47G 149G 24G
Jones et al. (1995)A, Brandt et al. (2000)B, Nomiyama et al. (2001)C, Holven et al. (2002)D, Parissis et al. (2002)E, Bottcher et al. (2003)F, Hieshima et al. (2003)G, Kagami
et al. (2003)H, Maheshwari et al. (2003)I, Struyf et al. (2003)J, Takahata et al. (2003)K, Antonelli et al. (2005)L, Chuang et al. (2005)M, Kagami et al. (2005)N, Yang et al.
(2005)O, Bauer et al. (2006)P, Sheikine et al. (2006)Q, Alzoghaibi et al. (2008)R, Narbutt et al. (2009)S, Pacheco-Rodriguez et al. (2009)T, Schiffer et al. (2009)U, Carreno
et al. (2010)V, Izukuri et al. (2010)W, Dong et al., 2011)X, Hernandez-Molina et al. (2011)Y, Burkhardt et al. (2012)z.
Family and members of chemokines are listed on the left. The predicted molecular weights (MW) of mature chemokine forms are denoted in kilodaltons (kD).
Reported serum or plasma concentrations of chemokines are grouped together in a single column. Italicized letter next to value designates reference source. BAL,
broncholalveolar lavage. All concentrations are reported as nanomolar (nM). Blanks indicate not determined.
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E. coli and P. aeruginosa (Schneider et al., 2005). Most other
antimicrobial proteins also exert antimicrobial effects at micro-
molar concentrations. One exception is bactericidal/permeability
increasing protein (BPI), which has activity against Gram negative
bacteria at nanomolar concentrations (Wiesner and Vilcinskas,
2010).
The other classes of antimicrobial proteins consist of linear
amphipathic helical proteins and peptides with high content of
certain amino acids such as histidine, glycine, proline, or tryp-
tophan. Since these groups have little similarity to chemokines,
readers can refer to other recent reviews for details (Wiesner and
Vilcinskas, 2010).
DEFINING ANTIMICROBIAL AND CHEMOTACTIC DOMAINS
There are no mutagenesis studies showing whether the antimi-
crobial and chemotactic regions of antimicrobial chemokines are
linked. The best-studied antimicrobial chemokine is CXCL9. Sev-
eral groups have identified CXCL9 antimicrobial activities against
S. pyogenes, S. aureus, B. anthracis, P. aeruginosa, and E. coli. Ini-
tially discovered as the monokine induced by gamma interferon
(MIG), CXCL9 is cleaved into several smaller forms endogenously
(Liao et al., 1995). These smaller proteins have C-terminal trunca-
tions and are able to activate CXCR3, albeit with less potency and
efficacy than full-length CXCL9. Mixtures of truncated CXCL9
proteins were separated into a high molecular weight and a low
molecular weight group, presumably each group having several
truncated forms. However, it is unknown whether these trun-
cated CXCL9 forms have antimicrobial properties. A summary
of functional analysis for CXCL9 is shown in Figure 3.
A 27 amino acid synthetic peptide consisting of the C-terminal
region of CXCL9 has been reported to be sufficient for antimi-
crobial activity (red boxed). This peptide is predicted to have an
amphipathic alpha helix structure. In contrast, a peptide spanning
the N-terminal region of CXCL9 with beta sheet structure had no
detectable antimicrobial activity (blue boxed). Both peptides have
overall cationic charge. Another group tested the N-terminal (50
amino acids) and C-terminal (19 amino acids, corresponding to
the alpha helix) domains of CXCL6 and found that the N-terminal
fragment had higher antimicrobial properties than the C-terminal
peptide (Linge et al., 2008). It may be that the whole protein is
needed for full antimicrobial properties.
Streptococcal cysteine proteinase (SpeB) from S. pyogenes and
subtilisin-like serine-proteinase (SufA) from Finegoldia magna can
degrade full-length CXCL9 to smaller proteins (Egesten et al.,
2009; Karlsson et al., 2009). By mass spectrometry, these proteins
were identified to have both N-terminal and C-terminal trun-
cations (Figure 3). Interestingly, both proteins retained antimi-
crobial properties for S. pyogenes. However there is a discrep-
ancy between the peptides in activating CXCR3. SpeB-degraded
CXCL9 cannot activate CXCR3, whereas SufA-degraded peptides
can. The authors did not individually purify and test each trun-
cated form of CXCL9. Therefore, it is possible that the least
processed form of CXCL9 by SufA is responsible for recep-
tor activation. In addition, SufA can also degrade CXCL10 and
CXCL11, causing both chemokines to lose both receptor activa-
tion and antimicrobial properties. More studies will be needed
to precisely determine specific regions necessary and sufficient
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FIGURE 3 | CXCL9 cleavage sites. CXCL9 has a signal sequence that is
cleaved before secretion. Blue box indicates an N-terminal peptide
corresponding to predicted beta sheet secondary structure. Red box
indicates a C-terminal peptide corresponding to predicted amphipathic
alpha helix secondary structure. R and Abx represent CXCR3 receptor
activation and antibiotic activities, respectively. ND, N, and Y, denote not
determined, negative, and positive (yes) activities, respectively.
Endogenous CXCL9 has several truncated forms. These forms have been
separated into two groups: high molecular weight (High MW) and low
molecular weight (Low MW) groups for receptor activation. SpeB and
SufA are two bacterial enzymes that cleave CXCL9. Arrows indicate where
the processing sites are located.
for chemotactic and antimicrobial properties, and whether these
regions overlap.
MECHANISM OF ACTIVITY
By electron microscopy criteria, antimicrobial chemokines appear
to induce lysis of the bacterial membrane (Hieshima et al., 2003;
Egesten et al., 2007; Linge et al., 2008). Since the outer membrane
of bacteria are highly anionic, charge interaction is thought to
mediate initial binding (Brogden, 2005). In eukaryotic cell mem-
branes, negatively charged phospholipids are sequestered in the
inner leaflet of the lipid bilayer, and the outer leaflet is composed
mostly of zwitterionic and uncharged lipids. Therefore, the lipid
content of the outer membranes of eukaryotic cells are devoid
of electrostatic charge (Wiesner and Vilcinskas, 2010). In con-
trast, both leaflets of bacterial cell membranes are enriched with
acidic phospholipids such as phosphatidylglycerol and cardiolipin,
making these membranes negatively charged.
The exact mechanism for antimicrobial killing is not known nor
is it known whether all chemokines kill microbial targets by a com-
mon mechanism. Defensins, which have been studied in greater
detail, are absorbed onto the bacterial membrane by electrostatic
attraction and subsequently aggregate there to cause local mem-
brane thinning and ion channel formation (Ganz, 2003). Rupture
of bacterial membranes has been demonstrated in S. pyogenes for
CXCL9, in E. coli for CXCL6, and in P. aeruginosa for CCL28
(Hieshima et al., 2003; Egesten et al., 2007; Linge et al., 2008).
For the bacterium responsible for anthrax, B. anthracis, the
membrane protein FtsX has been identified as a unique target for
CXCL10 (Crawford et al., 2011). The authors used a transposon-
based genetic screen to identify ftsX, and two other genes (BAS0651
and the cell wall autolysin lytE) to be critical for resistance
against CXCL10. B. anthracis genetically deficient in ftsX could
not bind CXCL10 as assessed by transmission electron microscopy.
FtsX is a cell division ABC transporter that is conserved among
Gram-positive and Gram negative bacteria. Comparative protein
analysis of FtsX with CXCR3, the receptor for CXCL10, showed
a 27-residue region of FtsX that has 45% similarity with the N-
terminal chemokine-binding domain of CXCR3. This is low, and
how FtsX actually functions in antimicrobial chemokine resistance
remains to be determined.
If charge–charge interaction were the sole means of chemokine-
binding and antimicrobial action, chemokines would not be
predicted to have antifungal properties since fungi have eukary-
otic membranes. Histatin, a known antifungal peptide, inhibits
C. albicans by binding to fungal mitochondria and inhibit-
ing respiration by inducing reactive oxygen species (ROS) for-
mation (Helmerhorst et al., 2001). The level of induced ROS
correlated with fungicidal activity. However, it is not known
whether antimicrobial chemokines act through similar path-
ways. The chemokine CCL28 has been shown to cause mem-
brane disruption in C. albicans by scanning electron microscopy
(Hieshima et al., 2003). How it binds to the fungal membrane
and the domain responsible for antifungal activities has not been
determined.
By whatever mechanisms chemokines kill pathogens, they do so
rapidly. CXCL6 can disrupt liposome membranes within minutes,
and pathogens treated with CCL28 show numerous surface blebs
within 1 h (Hieshima et al., 2003; Linge et al., 2008). It is unclear
whether gene activation or signal transduction needs to occur
for antimicrobial chemokines to kill targets. Unlike traditional
antibiotics, which work best on dividing organisms, antimicro-
bial proteins typically can exert effects on non-dividing organisms
(Wiesner and Vilcinskas, 2010).
The salt dependence seen with antimicrobial chemokines is typ-
ical of most antimicrobial proteins. With the exception of human
beta defensin 3, all human defensins exert antimicrobial properties
at ∼10 mM Na+. Killing of pathogens is thought to occur in vivo
even in host environments with >10 mM Na+ because defensins
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are packed in high concentration within granules. Activation and
degranulation of leukocytes by pathogens would produce very
high local concentrations of defensins for optimal antimicro-
bial effects. In addition, two recent reports have shown that the
antimicrobial activity of chemokines is not dependent on sodium
concentration for certain bacteria. In particular, CXCL9, CXCL10,
and CXCL11 are able to inhibit growth of S. pyogenes even in
150 mM sodium chloride solutions. The same chemokines could
also inhibit B. anthracis germination and growth in culture media
with serum.
INHIBITION OF ANTIMICROBIAL CHEMOKINES BY BACTERIA
In addition to degrading chemokines with SpeB, S. pyogenes pro-
duces additional factors that inhibit antimicrobial chemokines.
Streptococcal interleukin-8 inactivating cell envelope protease
(SpyCEP) cleaves CXCL1, 2, 6, and 8 (Zinkernagel et al., 2008),
and Streptococcal inhibitor of complement (SIC) binds CXCL9 to
inhibit its antimicrobial properties (Egesten et al., 2007). As men-
tioned previously, the bacterium F. magna expresses a subtilisin-
like serine-proteinase (SufA) that partially degrades CXCL9, abol-
ishing its antimicrobial activity (Karlsson et al., 2009). Therefore,
several bacteria have developed means to degrade antimicrobial
chemokines and evade host defense.
IN VIVO EVIDENCE FOR ANTIMICROBIAL PROPERTIES OF
CHEMOKINES
Many inflammatory chemokines with antimicrobial properties are
induced during inflammatory or infectious processes. It is unclear
to what extent control of pathogens depends on direct antimi-
crobial activities of chemokines versus recruitment of leukocytes.
One study demonstrated that neutralization of either CXCL9 or
CXCL10 but not CXCR3 (the receptor for CXCL9 and CXCL10)
increased susceptibility of C57BL/6 mice to B. anthracis (Crawford
et al., 2011). Increased mortality was shown to arise from extra-
pulmonary dissemination of bacteria to kidneys, spleen, and liver
and from toxemia with lethal factor. However, the bacterial load at
the site of inoculation, the lung, was similar between treated and
untreated mice.
We are not aware of genetic mutations in chemokine
genes leading to increased susceptibility to infectious diseases
in humans. However, there is persuasive evidence that the
chemokine system mediates control of pathogens in mam-
mals, including humans. For example, a form of congenital
neutropenia, WHIM syndrome, arises from gain-of-function
mutations truncating the C-tail of CXCR4 (Hernandez et al.,
2003). Patients with WHIM syndrome have recurrent bacter-
ial infections, especially in the sino-pulmonary tract, apparently
caused by neutropenia and hypogammaglobulinemia (Kawai and
Malech, 2009). However, this susceptibility appears to be due to
leukocyte trafficking defects, not direct antimicrobial effects of
chemokines.
FUTURE DIRECTIONS
There is no doubt that many chemokines have antimicrobial prop-
erties in vitro. However, the in vivo significance of chemokines as
antimicrobial agents is still unclear. Direct antimicrobial activity
will depend on the chemokine concentration and the environmen-
tal context between host and pathogen. In theory, chemokines
in mucosal surfaces might inhibit colonization of certain bac-
teria in the host since antibiotic usage has clearly been shown
to alter normal flora. New studies will be needed to determine
whether lack of constitutive chemokines affect skin and mucosal
flora.
Studying the domains important for antimicrobial activities
might lead to more potent antimicrobial peptides. Cationic charge
and amphipathic alpha helix secondary structure appears to be
important for antimicrobial properties. However, with the great
diversity of antimicrobial peptides there has been neither con-
sensus primary sequence nor a predominant tertiary structure.
This makes molecular modeling to generate more potent syn-
thetic antimicrobial proteins difficult. There is also the issue of
unwanted side effects. Several potent antimicrobial peptides have
systemic toxicity because they lyse red blood cells as well as
pathogen membranes (Wiesner and Vilcinskas, 2010). In addi-
tion, we have found that many chemokines can induce the release
of a virulence factor, protein A, in S. aureus (Yung et al., 2011).
This potentially would harm the host if bacteria deploy viru-
lence factors in response to chemokines. There is also evidence
that subinhibitory concentrations of aminoglycoside antibiotics
induce biofilm formation (Hoffman et al., 2005). Antibiotics
trigger a protective response by bacteria to form biofilms. Bac-
teria in biofilms are very difficult to eradicate and are gener-
ally thousands of times more resistant to antimicrobial therapy
than planktonic bacteria. In the same manner, antimicrobial pro-
teins might trigger a protective response by bacteria to form
biofilms.
Currently, there are no antimicrobial proteins in clinical use.
The antimicrobial peptide MSI-78 or pexiganan completed a phase
III clinical trial for the treatment of diabetic foot ulcers. MSI-78
was originally derived from magainan, an antimicrobial peptide
found on the skin of frogs (Zasloff, 1987). However, it failed to
receive approval from the FDA on the grounds that efficacy was
not sufficiently demonstrated. Few companies are actively devel-
oping antimicrobial proteins as therapeutics. Both MBI-226 (a
12 amino acid peptide developed for the prevention of catheter-
related bloodstream infections) and Neuprex (a recombinant frag-
ment of bactericidal/permeability increasing protein developed for
meningococcal meningitis) finished phase III clinical trials and
never made it to market. It is unclear how antimicrobial pro-
teins will be used in the clinics. Topical formulations to treat skin
infections may be most applicable but effective topical antiseptics
such as chlorhexidine already exist. To treat invasive infections,
an injectable or intravenous form would be needed since pro-
teins would most likely be degraded in the gastrointestinal tract. If
developed, such potential broad-spectrum antimicrobial peptides
might be useful in the setting of life-threatening infections caused
by multi-drug resistant organisms.
Even though antimicrobial chemokines have been shown
to generally disrupt bacterial membranes, unique targets on
pathogens may actually mediate killing. As mentioned previ-
ously, the cell membrane protein FtsX in B. anthracis binds
CXCL10 specifically and mediates antimicrobial chemokine resis-
tance. Understanding this pathway and determining whether the
same or related pathways exist in other organisms may lead to new
antibiotics.
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Genome-wide association studies have not linked increased
infection susceptibility to single nucleotide polymorphism in
chemokine genes. This could imply either no association, a weak
association that has not been analyzed, or redundancy of the
antimicrobial protein system. Further genetic studies in mice will
be able to address whether genetic deficiencies in chemokines cor-
relate with pathogen control, especially when compared with their
respective chemokine receptor deficient controls.
CONCLUSION
In conclusion, the utility of chemokines likely extends beyond
leukocyte recruitment. Understanding domains essential for
antimicrobial activities in antimicrobial chemokines could lead
to more potent antimicrobial peptides. In addition, spe-
cific pathways may be involved in pathogen recognition of
antimicrobial chemokines. Much work is needed to deter-
mine whether antimicrobial chemokines affect susceptibil-
ity to infection in humans, how chemokines kill microbes,
and whether antimicrobial chemokines can be use to treat
infections.
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